SCM
LKFT

Soleus Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Soleus Capital Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-98,800
Closed -$5.45M – 74
2021
Q4 		$5.45M Sell
98,800
-16,500
-14% -$861K 0.55% 36
2021
Q3 		$6.07M Buy
+115,300
New +$6.84M 0.95% 32

Other funds holding LKFT

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Soleus Capital Management's LKFT Position: Q1 2022 in Review

Soleus Capital Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2022, closing a stake of 98,800 shares — an estimated $5.45M sold.

Soleus Capital Management first reported a position in LKFT in Q3 2021 and held it in 2 quarters. The position peaked at $6.07M in Q3 2021. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2022.

  • Soleus Capital Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2022 after selling out during the quarter.
  • Soleus Capital Management sold 98,800 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2022, an estimated $5.45M.
  • Soleus Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2021 and held it in 2 quarters.
  • Soleus Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $6.07M in Q3 2021.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2022.

Based on Soleus Capital Management's 13F filing for Q1 2022, filed 16 May 2022.